Ajooni Biotech Limited Announces Financial Results and Unmodified Audit Opinion
Ajooni Biotech Limited's Board of Directors met on May 28, 2026. During the meeting, the Board considered and approved the audited financial results for the year ended March 31, 2026, along with the corresponding auditor's report and the declaration of an Un-Modified Opinion.Standalone Financial Results Overview
The standalone financial results for the quarter ended March 31, 2026, show the following performance metrics (figures in Lakhs):| Particulars | Quarter Ended 31.03.2026 | Quarter Ended 31.12.2025 | Quarter Ended 31.03.2025 | Year Ended (Audited) 31.03.2026 | Year Ended (Audited) 31.03.2025 |
|---|---|---|---|---|---|
| Revenue from operations | 6,062.21 | 587533 | 2,927.44 | 18,237.81 | 11,469.19 |
| Other income | 13,043 | 32.10 | 133.64 | 241.81 | 206.90 |
| Total income from operations | 6,192.64 | 5,907.43 | 3,061.08 | 18,479.62 | 11,676.09 |
| Cost of Material Consumed | 4,915.56 | 4,832.50 | 2,259.09 | 14,805.33 | 9,715.42 |
| Change In Inventories | (0.83) | (14.31) | 10.87 | (12.54) | (12.65) |
| Employee benefit expenses | 127.78 | 119.30 | 59.01 | 457.29 | 275.73 |
| Finance costs | 28.95 | 18.32 | 5.68 | 72.94 | 33.43 |
| Depreciation and amortization expenses | 89.79 | 81.47 | 38.10 | 220.63 | 109.35 |
| Other expenses | 919.36 | 634.42 | 497.14 | 2,362.14 | 1,121.88 |
| Total expenses | 6,080.61 | 5,671.70 | 2,869.89 | 17,905.79 | 11,243.16 |
| Profit/(Loss) before exceptional items and tax | 112.03 | 235.73 | 191.18 | 573.83 | 432.92 |
| Mat Credit Net Profit/(Loss) for the period/year | 94.72 | 164.80 | 154.38 | 432.19 | 337.20 |
| Total comprehensive income | 10.69 | 127.89 | 72.00 | 311.25 | 311.10 |
The Earnings Per Share (EPS) figures for the current period/year are detailed below:
| Metric | 31.03.2026 | 31.12.2025 | 31.03.2025 |
|---|---|---|---|
| EPS (Basic - Diluted) | 0.05 | 0.08 | 0.09 |
Balance Sheet Summary
The company's balance sheet as of March 31, 2026, shows total assets and equity and liabilities of 12,036.5 Lakhs.| Particulars (in Rs. Lakhs) | 31st March 2026 | 31st March 2025 |
|---|---|---|
| I. EQUITY AND LIABILITIES | ||
| Equity Share Capital | 3,444.87 | 3,444.87 |
| Other Equity | 5,674.28 | 5,363.02 |
| II. Non-Current Liabilities | ||
| Borrowings | 154 | 193.97 |
| Employee Benefit Obligations | 28.65 | 21.13 |
| III. Current Liabilities | ||
| Borrowings | 1,622.28 | 0.00 |
| Trade Payables | 891.41 | 349.52 |
| Employee Benefit Obligations | 1.69 | 0.93 |
| Other Current Liabilities (Net) | 153.01 | 102.42 |
| TOTAL | 12,036.5 | 9,505.11 |
Conversely, the total assets stand at 12,036.5 Lakhs as of March 31, 2026.
| Particulars (in Rs. Lakhs) | 31st March 2026 | 31st March 2025 |
|---|---|---|
| Non-Current Assets | ||
| Property, Plant and Equipment | 2,585.57 | 1,093.31 |
| Other Intangible Assets | 35.95 | 47.93 |
| Other Financial Assets | 1,500 | 1,506.79 |
| Other Non Current Asset | 173.3 | 240.11 |
| Current Assets | ||
| Inventories | 3,945.51 | 2,398.69 |
| Trade Receivables | 1,783.43 | 1,621.64 |
| Cash & Cash Equivalent (Bank Balances) | 41.9 | 683.02 |
| Loans | 1,414.92 | 1,330.65 |
| Other Financial Asset | 69.98 | 27.37 |
| Other Current Asset | 191.91 | 139.03 |
| TOTAL | 12,036.5 | 9,505.11 |
Cash Flow Highlights
The Cash Flow Statement for the year ended March 31, 2026, reports significant cash movements across operations, investing, and financing.| Activity | 2026 (Year Ended) | 2025 (Year Ended) |
|---|---|---|
| Net from Operating activities | 8750448 00 | 260962215 |
| Net Cash used in Investing activities | (157.707,011.95) | 135,487,221 71 |
| Net Cash used in financing activities | (64,171,868.65) | 41962727 |
| Net increase in cash & cash equivalents | 4189,746.07 | N/A |
| Cash and Cash equivalents at the End of the Year | 830161508 | 4281987 81 |
Audit and Compliance Findings
The Independent Auditor provided an opinion on the financial statements for the year ended March 31, 2026.Audit Opinion:
The financial statements were found to give a true and fair view of the state of affairs of the Company as at March 31, 2026, and its profit for the year ended on that date.
Internal Controls:
The audit also concluded that the Company has, in all material respects, an adequate internal financial controls system over financial reporting, and these controls were operating effectively as at March 31, 2026.
The Board of Directors' declaration confirmed that the auditors' report for the financial year ended March 31, 2026, contains an unmodified opinion.
AJOONI Stock Price Movement
On Wednesday, Ajooni Biotech Limited shares edged higher to close at ₹4.26, registering a 0.47% gain for the session. The stock saw robust trading activity, finishing the day on a volume of 161,088 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: